Clinical trial
A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
NCT00387686 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00387686 |
|---|---|
| Title | A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures |
| Official title | A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Fractures |
| Intervention type | Drug |
| Interventions | rhBMP-2/CPM |
| Enrollment | 367 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Oct 13, 2006 |
| Last update posted | Feb 28, 2013 |
| Countries | Argentina, Australia, Brazil, Canada, Finland, France, Germany, India, Latvia, Mexico, Poland, Romania and 6 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: